Interleukin-10 (IL-10) is an ideal candidate cytokine for AdCMVhIL-10 induced a prolongation of median survival suppressing the alloimmune response in transplantation.
Introduction
Liver transplantation is an effective therapy for both inherited and acquired disorders of the liver. However, allograft rejection is still a limiting factor to successful liver transplantation. To avoid graft rejection, it is now clinical practice that the immune response of the recipient must be continuously suppressed by systemic immunosuppressive therapy, eg glucocorticoids, cyclosporin, azathioprine, tacrolimus hydrate and muromonab-CD3. Unfortunately, these immunosuppressive therapies are not specific for the alloantigen. Consequently, they promote development of infection, diabetes, and hypertension in allograft recipients and are associated with an increased risk of future malignancy. 1 The development of new immunosuppressants with greater specificity for alloantigen and/or utilization of effective local drug delivery systems are essential to reduce the adverse consequences of systemic immunosuppression in recipients and to improve the quality and duration of life following transplantation.
The importance of cytokines and costimulatory molecules in the development of specialized T cells is now becoming clear. 2, 3 Newer immunosuppressants with minimal side-effects will be developed with an eye towards more specific intervention at the level of the microenvironment of lymphocyte priming and acti- vation. Interleukin-10 (IL-10) is an ideal candidate cytokine for suppressing the immune response in allotransplantation and has received growing attention for its therapeutic potential. IL-10 was originally described as a cytokine synthesis inhibitory factor. 4 IL-10 is produced by different cell types, including T cells, monocytes and B cells, after all activation. 5, 6 In vitro studies have shown that IL-10 indirectly prevents antigen-specific T cell proliferation by reducing the antigen-presenting capacity of monocytes through down-regulation of class II major histocompatibility complex (MHC) expression. 7 In addition, IL-10 directly suppresses T cell proliferation by specific inhibition of IL-2 production by T cells. 8 Similarly, IL-10 has potent inhibitory effects on alloantigen-induced proliferative and cytotoxic T cell responses. 9 Recently, it has been suggested that IL-10 drives the generation of a CD4 + T cell subset, and that designated as T regulatory cells type 1 (Tr1). 10 Tr1 suppresses antigen-specific immune responses and actively down-regulates pathologic immune responses in vivo. 10, 11 In addition, IL-10 shows anti-inflammatory activity by inhibiting the production of proinflammatory cytokines, such as IL-1␤, IL-6, IL-8 and tumor necrosis factor ␣(TNF-␣), 5,12,13 and upregulating monocyte production of soluble TNF receptor and IL-1Ra. 14 Overall, these biologic activities indicate that IL-10 is a potent negative regulator of immunoproliferative and inflammatory responses, including alloreactivity, and suggest that IL-10 is a beneficial cytokine for allogeneic organ transplantation. However, recombinant cytokines, including IL-10, are short-lived and have limited access to tissue interstitium in vivo. [15] [16] [17] The serum half-life of recombinant IL-10 (rIL-10) after a single injec-tion is several hours. 15, 16 This short half-life is likely to be an obstacle to the use of rIL-10 in transplantation. 18 Gene transfer techniques are attractive vehicles for prolonging the expression of short-lived proteins, such as cytokines. Previous reports have demonstrated successful ex vivo gene transfer to grafts using an adenovirus vector expressing the lacZ gene in solid organ transplantation. [19] [20] [21] [22] Furthermore, it has recently been shown that cytokine gene transfer by adenovirus vector-based techniques is efficient and may be used to achieve transient but continuous cytokine expression at different tissue sites. [23] [24] [25] [26] Theoretically, local production of the recombinant protein would result in donor-specific intragraft immunosuppression, with minimal effects on the systemic response to alloantigen. In this study, we constructed and characterized a replication-deficient adenovirus vector harbouring human IL-10 cDNA (AdCMVhIL-10). We sought to determine whether genetic modulation of the donor liver with AdCMVhIL-10 before transplantation could suppress the alloimmune response and prolong survival following orthotopic liver transplantation (OLT). These studies provide the basis for developing effective IL-10 gene therapy to suppress the immune response to liver transplantation. In addition, this work may have general implications for transplantation in other organs.
Results

Characterization of the adenovirus vector expressing hIL-10
In the initial studies, we examined whether human IL-10 (hIL-10) could be excreted from cells transduced with AdCMVhIL-10 in vitro. We also investigated the timecourse of hIL-10 production from AdCMVhIL-10-transduced cells and then determined when hepatic grafts should be transduced with recombinant adenovirus vectors in vivo. Figure 1 shows the kinetics of hIL-10 production from AdCMVhIL-10-transduced RCN-9 cells (rat colon adenocarcinoma cell line) in vitro. Release of hIL-10 was detected only from cells infected with AdCMVhIL-10 and not with control vector (data not shown). Significant levels of hIL-10 were noted at day 1 after transfection, increasing to day 3. Levels of hIL-10 release appeared to be maximal between days 2 and 3. These results demonstrate excretion of hIL-10 by AdCMVhIL-10-transduced cells. From these results, we decided to transduce hepatic grafts with AdCMVhIL-10 24-48 h before transplantation in order to produce hIL-10 maximally during the initial stages of transplantation.
Local hIL-10 production of AdCMVhIL-10-transduced hepatic grafts in vivo Transgene expression in transduced liver allografts was documented by reverse transcriptase-polymerase chain reaction (RT-PCR) in liver specimens on day 3 after OLT. Messenger RNA for human IL-10 sequence was detectable at high levels only in AdCMVhIL-10-transduced hepatic grafts (data not shown). Moreover, to verify successful transduction to the hepatic allograft of AdCMVhIL-10 and local production of hIL-10 within the transduced hepatic graft, hIL-10 was measured in serum collected from the suprahepatic vena cava (SH-VC) and the infrahepatic vena cava (IH-VC) of transplanted animals on day 3 after OLT, using an enzyme-linked immunosorbent assay (ELISA) kit. As shown in Table 1 , an increase in hIL-10 levels was detected in AdCMVhIL-10-transduced hepatic grafts. Successful transduction to the hepatic allograft of AdCMVhIL-10 was thus confirmed at the protein level. Moreover, we found that levels of hIL-10 from the SH-VC were significantly (1.48-fold) higher than those from the IH-VC (P = 0.013), indicating both local production and efficient excretion of the protein from the transduced allograft. However, human IL-10 levels also were detected minimally with AdCMVlacZtransduced hepatic grafts and untreated grafts. This may be due to cross-reactivity with other rat cytokines. These results demonstrate that adenovirus-mediated gene transfer into an hepatic graft enables efficient and local production of the recombinant protein within the graft.
AdCMVhIL-10 prolongs hepatic allograft survival Survival in the high responder DA (RT.1 a ) to Lewis (RT.1 l ) combination was compared in the following three experimental groups: group I received hepatic grafts transduced with AdCMVhIL-10; group II received hepatic grafts transduced with AdCMVlacZ; and group III were controls receiving unmodified grafts. There were five rats per group. Adenovirus vectors were injected into the portal vein 24-48 h before OLT. Survival was assessed daily. (Results for survival are shown in Table 2 .) Group I animals had a significantly prolonged median survival of more than 87 days, with two of five animals surviving more than 100 days, compared with 11 days for group II (P = 0.0021) and 11 days for group III (P = 0.0021). No surgical mortality occurred. Interestingly, hIL-10 proteins were not detected in the circulation on day 21 after OLT in group I (data not shown). Presumably, AdCMVhIL-10-transduction results in immunologic modulation of antigen-presenting cells in the hepatic graft and/or other immune cells of the recipient. Consequently, group I animals survived longer despite undetectable hIL-10 levels. These results indicate that hepatic grafts transduced with an adenovirus vector harbouring Donor livers were transduced with 1 × 10 10 p.f.u. of recombinant adenoviral vectors via the ileocecal vein 24-48 h before orthotopic liver transplantation (OLT). OLT was performed in the combination of DA to Lewis. On day 3 after OLT, serum was collected from the suprehepatic vena cava (SH-VC) and infrahepatic vena cava (IH-VC), as shown in Figure 3 . All data are expressed as mean ± s.e.m. for two to three recipient rats per group. *P = 0.013 versus IH-VC (group I). a Rats died with functioning hepatic grafts. *P = 0.0021 versus group II; **P = 0.0021 versus group III. The symbol 'Ͼ' denotes that the liver was still functioning at the time of submission of data.
hIL-10 cDNA blunt the alloimmune response and prolong survival following OLT.
Histologic assessment of AdCMVhIL-10-transduced hepatic grafts Biopsies from the hepatic allografts transduced with AdCMVhIL-10 (group I) were performed on day 8 after OLT. They demonstrated that only a few lymphoid cells had infiltrated in both the periportal parenchyma and portal area without obvious venous endothelialitis (Figure 2a ). Zonal necrosis and cholestasis were not noted. These findings were considered to be nonspecific reactions, but not rejection. Autopsies of the three rats that died on days 56, 69 and 87 in group I revealed portal fibrosis with marked proliferation of bile ducts (Figure 2b ). Portal lymphoid cell infiltration was minimal. Venous endothelialitis was not presented. These findings resulted from ischemic cholangitis as described previously. 27 The deaths were not due to liver failure because of the absence of graft rejection reaction. In contrast, autopsies in groups II and III demonstrated evidence of zonal necrosis and confluent loss of hepatocytes, and massive mononuclear cell infiltration corresponding to advanced acute rejection (Figure 2c and d) . 27 All of these animals died by day 14 from massive liver failure with jaundice and ascites, consistent with untreated acute allograft rejection. These results indicate that pretreatment of hepatic grafts with an adenovirus vector expressing hIL-10 diminishes the degree of mononuclear cell infiltration, apparently suggesting that IL-10 suppresses the alloimmune response of the rat grafted liver.
Preservation of liver function in AdCMVhIL-10-transduced hepatic grafts Table 3 shows liver function on day 3 after OLT. Marked elevations in transaminases, total bilirubin (T.Bil), and alkaline phosphatase (ALP) were detected in groups II and III. However, group I exhibited only mild elevations in transaminases and ALP and no elevation in T.Bil (P Ͻ 0.05). These results correlate well with the liver histology (Figure 2a-d) . In general, an acute rejection reaction, manifested by lymphoid cells appearing in the portal area, occurs early on day 2 after OLT in nontreated allografts. 27 On day 3, untreated grafts demonstrated ubiquitous portal lymphoid cell infiltration, endothelialitis with tenting of the endothelium in both portal and central veins and bile-duct damage. 27 In addition, in the initial stage after OLT, biochemical features were attributable to operative trauma and ischemia/ reperfusion injury during cold preservation. 28, 29 Biochemical features on day 3 were thus likely to be influenced by these three factors. Our results suggest that IL-10 may play a beneficial role in the prevention of ischemia/reperfusion injury and acute allograft rejection.
Discussion
Recently, gene transfer techniques have been investigated to avoid graft rejection, 23, 26, [30] [31] [32] [33] using delivery of immunomodulating molecules 23, 26, [30] [31] [32] or alloantigens 33 within the graft. The rationale behind local immunosuppression is based on the following two hypotheses: first, that rejection can be effectively suppressed by controlling only those immunologic events that occur at the graft site, and second, that by administering immunosuppressants directly into the allograft, one can simultaneously prevent rejection and diminish or eliminate both drugspecific and general adverse consequences of systemic immunosuppression. 1 We proposed this technique of in vivo gene transfer to induce local delivery of IL-10 as an immunosuppressant to inhibit the alloimmune response. Previous studies have reported that the serum half-life of recombinant hIL-10 after a single injection was several hours, 15, 16 suggesting limited access to organ tissue in vivo. 17 Furthermore, it has been reported that a single injection of recombinant viral IL-10 (rvIL-10), encoded by the Epstein-Barr virus and structurally homologous to murine and human IL-10, 34 had no effect on cardiac allograft survival. 32 mRNA for human IL-10 was detectable at high levels only in AdCMVhIL-10-transduced hepatic grafts (data not shown). Moreover, we were able to detect the excreted hIL-10 protein in the circulation of recipients with AdCMVhIL-10-transduced hepatic grafts by a commercially available ELISA kit ultrasensitive and specific for human IL-10, demonstrating the successful adenovirus-mediated in vivo gene transfer and efficient excretion of hIL-10 from the transduced allograft. Moreover, levels of hIL-10 from the suprahepatic vena cava were significantly higher than those from the infrahepatic vena cava, strongly suggesting that hIL-10 levels within the microenvironment of the hepatic graft are higher than the general circulation. Drazan et al 35 reported that detection of the recombinant viral IL-10 was limited to the allograft without measurable levels in peripheral blood. These findings support our suggestion. Presumably, it is because the limit of their ELISA is higher than that of the kit we used that they could not detect levels of IL-10 in peripheral blood. It should also be noted that there was no mortality due to the known toxic effects of IL-10, such as pulmonary, cerebral, or intestinal bleeding, diarrhea, or a flu-like syndrome. 25, 36 In the current study, AdCMVhIL-10-transduced hepatic grafts produced enough hIL-10 to suppress the alloimmune response, without side-effects or toxicity. Consequently, in vivo hIL-10 gene transfer into the hepatic graft produces local immunosuppression; future studies are needed to investigate this physiology.
Figure 2 Histologic findings in hepatic grafts after hematoxylin and eosin staining (×50). (a) On day 8 after transplantation, AdCMVhIL-10-transduced hepatic grafts demonstrate rare lymphoid cells and plasma cells infiltrating into the periportal and portal area without obvious endothelialitis and cholestasis. (b) The grafted liver obtained from autopsy on day 69 shows portal fibrosis with marked proliferation of bile ducts. Lymphoid cell infiltration is minimal. In contrast, the grafted livers obtained from autopsy of AdCMVlacZ-transduced grafts (c) and nontransduced grafts (d) demonstrate zonal necrosis, confluent loss of hepatocytes, and massive mononuclear cell infiltrate, corresponding to advanced, severe acute rejection.
IL-10 is a potent negative regulator of immunoproliferative and inflammatory responses, including alloreactivity.
2,4-14 We selected human IL-10 because of its detectability in the circulation of recipient rats using commercially available ELISA kits. Qin et al 32 reported that a retroviral vector encoding vIL-10 significantly prolonged nonvascularized cardiac allograft survival by inducing local immunosuppression. In retrovirusmediated gene transfer, the transgene product is generally present on a long-term basis as retroviral vectors integrate into host cell DNA. This approach might cause long-term immunosuppression. By contrast, an adenovirus vector provides high transduction efficiency but transient expression. Maximal production of IL-10 from AdCMVhIL-10-transduced cells occurred between days 2 and 3, after which production decreased gradually until day 6 (Figure 1 ). This dovetails with the clinical management of transplantation, in which massive immunosuppression is needed during the early post-transplant period, with requirements decreasing thereafter. Adenovirus vectors are therefore thought to be attractive and suitable vehicles for cytokine gene therapy for immunosuppression in transplantation. However, Qin et al 23 reported that the administration of a single dose of adenovirus vector encoding vIL-10 did not prolong nonvascularized cardiac allograft survival because vIL-10 was expressed for only a short period after transplantation. These data are not consistent with our results.
What then are the possible explanations for our successful findings? One possibility is that our transplantation model includes vascularity; endothelial cells constitutively express MHC class II antigens, 37, 38 in contrast to the nonvascularized cardiac transplantation model. IL-10 may prevent alloantigen-specific T cell proliferation indirectly by down-regulation of class II MHC expression.
7 Another possibility is the difference in transducibility to grafted organs with an adenovirus vector. In vivo gene transfer with adenovirus vector is more efficient in the liver than in other organs. 39, 40 Furthermore, liver grafts are generally considered to be more tolerant to graft rejection than the heart, kidney, or pancreas. Olthoff et al 30 reported that rat hepatic allografts transduced ex vivo with an adenovirus vector encoding CTLA-4Ig induced donor-specific transplantation unresponsiveness. However, the half-life of immunoglobulin is likely to be much longer than most cytokines, so that it would seem that transduction with CTLA-4Ig provides little advantage over adenovirus-mediated gene therapy. Furthermore, it is also possible that our transduced hepatic graft may produce enough IL-10 at the initial phase of the alloimmune response because of gene transfer 24-48 h before grafting. In contrast, introduction of IL-10 after the onset of acute rejection may not impede the effector phase of the immune response and may therefore not result in long-lasting unresponsiveness. The importance of IL-10 in the initial alloimmune response after OLT is supported by the fact that group I animals survived despite undetectable hIL-10 levels on day 21. A previous study reported that high levels of IL-10 secretion before bone marrow transplantation were correlated with a successful outcome, 41 consistent with our results. To date, gene transfer into grafts has been achieved by modifying the graft either ex vivo just before grafting, [19] [20] [21] [22] 30 or in vivo upon grafting. 23, 26, 32, 33 Our successful outcome following in vivo IL-10 gene transfer before grafting provides the basis for effective IL-10 gene therapies to suppress the immune response following allotransplantation.
In summary, our data demonstrate successful genetic modulation of hepatic graft with recombinant adenovirus vector harbouring IL-10 cDNA to suppress the local immune response following liver transplantation. Although the molecular and biologic mechanisms remain to be clarified, the observations in this paper suggest that IL-10 may induce profound T cell unresponsiveness. Currently, we are investigating the beneficial effects of this vector in lung and vascularized cardiac transplantation.
Materials and methods
Construction of AdCMVhIL-10
A 1600-bp fragment of hIL-10 cDNA was excised from pH15C (purchased from ATCC, Rockville, MD, USA) by BamHI digestion. The shuttle plasmid p⌬E1Z(A), a derivative of p⌬E1sp1A, 42 was obtained from Atsushi Miyanohara (UCSD Program in Human Gene Therapy, La Jolla, CA, USA). The IL-10 fragment was then subcloned into the BamHI site located 3′ of the human cytomegalovirus (hCMV) promoter in p⌬E1Z(A) to generate the recombinant plasmid p⌬E1Z(A)hIL-10. This plasmid was cotransfected into 293 cells, along with plasmid pJM17, 42 to rescue the E1-and E3-defective adenovirus vector expressing hIL-10, AdCMVhIL-10, by homologous recombination. A similar adenovirus vector expressing E. coli ␤-galactosidase from the hCMV promoter, AdCMVlacZ, was provided by Atsushi Miyanohara. 42 AdCMVlacZ was used as a control throughout this study. Virus stocks were propagated in 293 cells. The viral preparations were purified by two CsCl density ultracentrifugations, dialyzed, and stored in 10% glycerol in PBS at −70°C. The titers of the viral stocks were determined by plaque assay using 293 cells. 43, 44 All vectors were adjusted to 1 × 10 10 p.f.u./ml in PBS.
Animals
Inbred male DA (RT.1 a ) and Lewis (RT.1 l ) rats weighing 200 g were obtained from SLC (Atsugi) and Charles River (Hamamatsu), Japan, respectively. All animals were fed rat food ad libitum with free access to water. They were housed in accordance with institutional animal care policies.
In vivo gene transfer to hepatic grafts Donor rats were anesthetized with diethylether, and ventral midline incisions exposed the ileocecal vein. Donor livers were transduced with 1 × 10 10 p.f.u. of recombinant adenovirus vectors via the ileocecal vein 24-48 h before OLT.
Orthotopic liver transplantation OLT were performed in the strong rejecter combination of DA (RT.1 a ) to Lewis (RT.1 l ), as described previously. [45] [46] [47] The animals were anesthetized with diethylether. The donor livers were completely skeletonized. After injection of 150 IU of heparin intravenously, 5 ml of cold Ringer's lactate solution was perfused via the portal vein, and the liver was removed. The isolated livers were stored in cold Ringer's lactate solution during recipient preparation. The livers were transplanted orthotopically into recipient rats. In brief, the suprahepatic vena cava of the graft was anastomosed to the recipient's vena cava with a running suture; the graft portal vein and infrahepatic vena cava were connected to those of the recipient with a cuff technique; the graft hepatic artery was anastomosed to the recipient's right renal artery with a suture, 48 and the bile ducts of the graft and recipient were connected using a splint tube. The average anhepatic time was 15 min. Survival was followed daily, and autopsies were performed in all recipients.
Kinetics of hIL-10 production from AdCMVhIL-10-transduced cells For in vitro kinetics of hIL-10 production, 1 × 10 6 cells per well of RCN-9 cells (rat colon adenocarcinoma cell line) were incubated with AdCMVhIL-10 at a multiplicity of infection (MOI) of 5 in a six-well plate. The culture supernatants were replaced with new media every 24 h after gene transduction. The human IL-10 concentration was measured with a commercial ELISA kit specific for human IL-10 (Biosource International, Camarillo, CA, USA). Results are reported as IL-10 production/ml/10 6 cells/24 h. The lower limit of this assay was 208 fg/ml.
Assay of human IL-10 serum levels A schematic representation for collecting serum is shown in Figure 3 . The animals with OLT were anesthetized with diethylether. After orotracheal intubation, they were ventilated with room air using a mechanical ventilator, and both median sternotomy and laparotomy were performed. To achieve complete vascular isolation of the liver, the venous inflow and outflow routes were clamped with vessel clips: the inferior vena cava (IVC) was occluded between the liver and the right atrium and between the liver and the renal veins. Thereafter, blood samples were collected from the SH-VC and the IH-VC. Human IL-10 was quantified using the commercial ELISA kit.
Histologic study
The excised livers were fixed in 10% formalin and embedded in paraffin. Sections were cut at 4 m, and histologic assessments were performed by hematoxylin and eosin staining.
Biochemical assay
When recipient rats in groups I, II and III were killed on day 3 after OLT, blood samples were collected from the inferior vena cava. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), T.Bil and ALP levels were measured with the Automatic Analyzer Hitachi 7150 (Tokyo, Japan) using a commercially available kit (Wako Pure Chemical, Osaka, Japan).
Statistical analysis
Statistical analysis and correlations were performed using commercial computer software (Stat View J; Abacus Concepts, Berkeley, CA, USA). Group comparisons of continuous data were made by Student's t test. Survival data were analyzed by Kaplan-Meier, and significance was determined by the log-rank test. P values less than 0.05 were considered significant.
